Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today all resolutions were passed.download full film iBoy
As a result the Board now has authority to utilise the Equity Financing Facility provided by Bracknor, details of which were provided in the 22 February 2017 announcement.
The Company continues to consider a number of financing options in addition to the Bracknor facility and the financing agreement with Blackfinch Investment Limited that was announced on 27 March 2017.
For further information, please contact:
|Advanced Oncotherapy plc||www.avoplc.com|
|Nicolas Serandour, Chief Executive Officer||Tel: +44 20 3617 8728|
|Michael Sinclair, Executive Chairman|
|Stockdale Securities (Nomad & Joint Broker)||Tel: +44 20 7601 6100|
|Antonio Bossi / David Coaten|
|Stifel Nicolaus Europe (Joint Broker)||Tel: +44 20 7710 7600|
|Walbrook PR (Financial PR & IR)||Tel: +44 20 7933 8780 or email@example.com|
|Paul McManus||Mob: +44 7980 541 893|
|Anna Dunphy||Mob: +44 7876 741 001|
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac for Image Guided Hadron Therapy (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.